

RE: [REDACTED]

From [REDACTED]

Date Sat 2021-02-20 23:45

To Yellow Card Mailbox <yellow.card@mhra.gov.uk>

Dear [REDACTED]

I am not his doctor. It is the student's father who has told me of the reaction. [REDACTED]
[REDACTED] have emailed him, asking him to forward your email to [REDACTED] consultant.

With best wishes

[REDACTED]
[REDACTED]
Professor of Orthopaedic Sciences
Honorary Consultant Orthopaedic Surgeon

School of Medicine

University of Nottingham

[REDACTED] Medical School, QMC

Nottingham, NG7 2UH

[REDACTED]
If this email has been sent outside your normal working hours then please do not feel obliged to respond until your next working day.



From: Yellow Card Mailbox <yellow.card@mhra.gov.uk>

Sent: 19 February 2021 20:07

To: [REDACTED]

Subject: FW: [REDACTED]

[REDACTED]
Cripps Medical Centre
NG7 2UH
Date 19/02/2021

MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom
gov.uk/mhra

Dear [REDACTED]

Local Identification Number:

Patient Initials: [REDACTED] **Patient Age:** 19 Years **Patient Sex:** Male

Yellow Card Reference Number: [REDACTED]

Thank you for taking the time to complete a Yellow Card report on a suspected side effect to the COVID-19 Vaccine AstraZeneca.

In view of the nature of the reaction you reported, please would you be kind enough to provide us with some additional details. You can return this information to us via email at yellowcard@mhra.gov.uk. Please quote the above Yellow Card reference number with all correspondence. In particular, it would be helpful to have the following information, if available:

- Could you please confirm if the diagnosis of immune thrombocytopenia was confirmed following haematology review?
- Was a unifying diagnosis for both thrombosis and thrombocytopenia confirmed?
- Could you please confirm if there was involvement of any other cell lines, or if platelets were the only cell line affected?
- Please provide information on any other potential causes of thrombocytopenia excluded eg: infectious causes, malignancy including metastatic disease, leukaemia, myelofibrosis, lymphoproliferative disorders, thrombotic thrombocytopenic purpura, disseminated intravascular coagulation, HITT syndrome
- Was there a known history or new diagnosis of autoimmune/ inflammatory disease eg: SLE, antiphospholipid syndrome?
- Were any medications with a potential thrombocytopenic effect to be taken concomitantly prior to the event eg: heparin, alemtuzumab, sodium valproate.
- Was the patient known to be on anticoagulation?
- Was there any evidence of preceding infection?
- Please provide the blood film/ blood smear report if available.
- Please provide nadir platelet counts and relevant blood results where available. If sequential blood results are available, please provide this.
- Please provide any radiological imaging reports or a summary of these reports.
- Was there any relevant medical history?
- Were any other vaccines administered recently? If yes, please could you specify which vaccines were administered?
- Please let us know about the outcome of the event eg: recovering, not resolved, ongoing?
- Please provide information about response to treatment eg: IVIg/ steroids.
- Were there any other concurrent events that may have contributed to thrombocytopenia?
- Please provide information on any other potential risk factors for thrombosis eg: active malignancy, intracranial malignancy, intracranial infection, significant dehydration, immobility, previous DVT, protein C and S deficiency, systemic inflammatory diseases, recent CNS trauma/ surgical intervention, acquired prothrombotic states (including nephrotic syndrome)
- Could you let us know if there is any other relevant information you can provide that has not already been addressed above.

All information provided is held in strict confidence and handled in line with our Yellow Card Privacy Policy, which can be found at <https://yellowcard.mhra.gov.uk/privacy-policy/>. If you wish to request a copy of the information we hold on your case or a copy of your report as it appears in our database, please write to us at the address above or email yellow.card@mhra.gov.uk citing your case reference number and details of your request.

Your contribution to the UK's Adverse Drug Reaction Reporting Scheme is greatly appreciated. This provides an important early warning of previously unrecognised adverse effects which allows us to take appropriate action to improve the safe use of medicines.

You can find out more about the suspected Adverse Drug Reactions we have received at www.mhra.gov.uk/yellowcard.

Additionally, you can stay up to date on the latest advice for the safe use of medicines by reading our monthly bulletin Drug Safety Update, which is available on our website at www.gov.uk/drug-safety-update. You can receive a notification of each new bulletin by sending your email address to registration@mhradrugsafety.org.uk.

Yours sincerely,

Vigilance and Risk Management of Medicines

If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications.

For more information on the Department of Health's email policy, click

DHTermsAndConditions

This message and any attachment are intended solely for the addressee and may contain confidential information. If you have received this message in error, please contact the sender and delete the email and attachment.

Any views or opinions expressed by the author of this email do not necessarily reflect the views of the University of Nottingham. Email communications with the University of Nottingham may be monitored where permitted by law.